




RealRate

PHARMACEUTICAL 2021

HERON THERAPEUTICS INC. DE
Rank 294 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of HERON THERAPEUTICS INC. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HERON THERAPEUTICS INC. DE compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 95% points. The greatest weakness of HERON THERAPEUTICS INC. DE is the variable Research and Development, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -281%, being 73% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	314,196
Cost of Goods Sold	36,189
Intangible Assets	0
Liabilities, Current	102,503
Liabilities, Non-Current	14,561
Other Assets	16,623
Other Compr. Net Income	172
Other Expenses	63,853
Other Liabilities	0
Other Net Income	885
Property and Equipment	22,737
Research and Development	174,533
Revenues	88,638
Selling, General and Administrative Expense	42,226

Output Variable	Value in 1000 USD
Assets	353,556
Liabilities	117,064
Expenses	316,801
Stockholders Equity	236,492
Net Income	-227,278
Comprehensive Net Income	-227,192
Economic Capital Ratio	-281%